Shots:
- The US FDA has approved Ennumo, a biosimilar to Neulasta (pegfilgrastim), expanding Accord’s biosimilar portfolio & supporting its goal to launch 20 biosimilars in the US by 2030
- Ennumo is approved for adults & pediatric pts (newborn & older) to reduce incidence of infection in febrile neutropenia in non-myeloid malignancies receiving myelosuppressive anti-cancer drugs & to improve survival following myelosuppressive radiation exposure (Hematopoietic Subsyndrome of Acute Radiation Syndrome)
- Pegfilgrastim is a recombinant granulocyte colony-stimulating factor (G-CSF) that stimulates neutrophil production to reduce febrile neutropenia & infection risk following myelosuppressive CT
Ref: PRnewswire | Image: Accord BioPharma | Press Release
Related News: Accord BioPharma Reports the US FDA Approval of Immgolis and Immgolis Intri (Biosimilar, Simponi and Simponi Aria)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
